Literature DB >> 33439945

Heparin solution in the prevention of occlusions in Hickman® catheters a randomized clinical trial.

Sandra Regina da Silva1, Mitzy Tannia Reichembach2, Letícia Pontes2, Gisele de Paula E Silva Carneiro Mendes de Souza1, Solena Kusma3.   

Abstract

OBJECTIVE: to evaluate the effectiveness of the 50 IU/mL heparin solution compared to the 0.9% isotonic saline solution in preventing occlusion of the double lumen Hickman® catheter, 7 and 9 French, in patients undergoing hematopoietic stem cell transplantation.
METHOD: a triple-blind randomized clinical trial. 17 double-lumen catheters (heparin group: n=7 and 0.9% isotonic saline group: n=10) were analyzed in which the two catheter routes were evaluated separately, totaling 34 lumens. The outcome variables were occlusion without reflux and complete occlusion. Descriptive analyses were performed using the Chi-square test and, of survival, according to the Kaplan-Meier test.
RESULTS: the mean number of days until the occlusion outcome was 52 in the heparin group and 13.46 in the 0.9% isotonic saline group in the white catheter route (p<0.001). In the red route, the mean follow-up days in the heparin group were 35.29, with no occlusion and 22.30 in the 0.9% isotonic saline group until the first occlusion (p=0.030).
CONCLUSION: blocking with 50 IU/mL heparin solution is more effective than 0.9% isotonic saline in preventing occlusion of the Hickman® catheter. Brazilian Registry of Clinical Trials: RBR-3ht499.

Entities:  

Year:  2021        PMID: 33439945     DOI: 10.1590/1518-8345.3310.3385

Source DB:  PubMed          Journal:  Rev Lat Am Enfermagem        ISSN: 0104-1169


  2 in total

Review 1.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

2.  Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins.

Authors:  Aleksandra Jakimczuk; Bartlomiej Kalaska; Kamil Kamiński; Joanna Miklosz; Shin-Ichi Yusa; Dariusz Pawlak; Krzysztof Szczubiałka; Andrzej Mogielnicki
Journal:  J Clin Med       Date:  2022-04-16       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.